Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
Cellular and Molecular Gastroenterology and Hepatology|September 6, 2018
Increased Pancreatic Protease Activity in Response to Antibiotics Impairs Gut Barrier and Triggers ColitisHongsup Yoon, Monika Schaubeck, Ilias Lagkouvardos, et al.Digestive Diseases and Sciences|June 21, 2015
The Toxin-Producing Pathobiont Klebsiella oxytoca Is Not Associated with Flares of Inflammatory Bowel DiseasesInes Zollner-Schwetz, Kathrin A T Herzog, Gebhard Feierl, et al.The Oncologist|February 25, 2017
Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical OutcomeFrancesco Panzuto, Elettra Merola, Marianne Ellen Pavel, et al.Journal of Immunology (Baltimore, Md. : 1950)|June 15, 2014
Opposing roles of prostaglandin D2 receptors in ulcerative colitisEva M Sturm, Balazs Radnai, Katharina Jandl, et al.Therapeutic Advances in Hematology|January 6, 2022
Antibiotic use and ileocolonic immune cells in patients receiving fecal microbiota transplantation for refractory intestinal GvHD: a prospective cohort studyWalter Spindelboeck, Bettina Halwachs, Nadine Bayer, et al.The Journal of Clinical Endocrinology and Metabolism|March 22, 2017
Functional Imaging in the Follow-Up of Enteropancreatic Neuroendocrine Tumors: Clinical Usefulness and IndicationsElettra Merola, Marianne E Pavel, Francesco Panzuto, et al.Annals of Surgical Oncology|November 14, 2019
Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?Elettra Merola, Anja Rinke, Stefano Partelli, et al.Inflammatory Bowel Diseases|July 18, 2023
Prediction of Response to Systemic Corticosteroids in Active UC by Microbial Composition-A Prospective Multicenter StudyAndreas Blesl, Philipp Wurm, Silvio Waschina, et al.Gut|January 15, 2017
European consensus conference on faecal microbiota transplantation in clinical practiceGiovanni Cammarota, Gianluca Ianiro, Herbert Tilg, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2021
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)Jaume Capdevila, Nicola Fazio, Carlos Lopez, et al.Pageof 3